| NATAP http://natap.org/
In the absence of an effective vaccine, daily
administration of anti-retroviral drugs is the most effective treatment for
HIV. However, low patient compliance rates combined with the virus's ability
to easily mutate has led to the emergence of drug-resistant strains that are
difficult to treat.
Professor Berkhout from the University of Amsterdam is
investigating a novel gene therapy that has long-lasting effects even after
a single treatment. It involves delivering antiviral DNA to the patients'
own immune cells that arms them against viral infection. "This therapy would
offer an alternative for HIV-infected patients that can no longer be treated
with regular antivirals," he suggested.
The therapy involves extracting and purifying blood stem
cells from the patient's bone marrow. Antiviral DNA is transferred to the
cells in the laboratory, after which the cells are re-injected into the
body. The DNA encodes tiny molecules called small RNAs that are the mirror
image of key viral genes used by HIV to cause disease. The small RNAs float
around inside the immune cell until they encounter viral genes which they
can stick to like Velcro™. This mechanism, called 'RNA interference' can
block the production of key viral components from these genes.
Transferring the antiviral DNA to stem cells would help to
restore a large part of the patient's immune system. "Stem cells are the
continually dividing 'master copy' cells from which all other immune cells
are derived. By engineering the stem cells, the antiviral DNA is inherited
by all the immune cells that are born from it," explained Professor Berkhout.
The group hopes to start clinical trials of the therapy
within 3 years. "So far, very promising results have been obtained in the
laboratory, and we are now testing the safety and efficacy in a pre-clinical
mouse model," said Professor Berkhout. |